Yuval Cohen - Feb 12, 2024 Form 4 Insider Report for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Signature
/s/ Yuval Cohen
Stock symbol
CRBP
Transactions as of
Feb 12, 2024
Transactions value $
$0
Form type
4
Date filed
2/14/2024, 03:19 PM
Previous filing
Jan 30, 2024
Next filing
Jun 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRBP Common Stock, par value $0.0001 per share Award $0 +73.9K +707.42% $0.00 84.4K Feb 12, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRBP Stock Option (right to buy) Award $0 +73.9K $0.00 73.9K Feb 12, 2024 Common Stock 73.9K $23.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 12, 2024, the Reporting Person was granted 73,947 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001.25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on February 12, 2025. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.
F2 The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 12, 2025, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 12, 2025.